BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome

Leukemia Research

Volumn 38, Issue 4, 2014, Pages 454-459

  Elias, Marjanu Hikmah ^a   Baba, Abdul Aziz ^a   Azlan, Husin ^a   Rosline, Hassan ^a   Sim, Goh Ai ^b   Padmini, Menon ^c   Fadilah, S Abdul Wahid ^d   Ankathil, Ravindran ^a  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b HOSPITAL PULAU PINANG   (Malaysia)

^c HOSPITAL RAJA PERMAISURI BAINUN   (Malaysia)

^d UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

BCR ABL dependent mechanisms; Chronic myeloid leukemia; Imatinib mesylate; Mutation; Tyrosine kinase domain

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; BCR ABL GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; POINT MUTATION; PRIORITY JOURNAL;

BCR-ABL DEPENDENT MECHANISMS; CHRONIC MYELOID LEUKEMIA; IMATINIB MESYLATE; MUTATION; TYROSINE KINASE DOMAIN;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAMIDES; CATALYTIC DOMAIN; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENE FREQUENCY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALAYSIA; MALE; MIDDLE AGED; MUTATION, MISSENSE; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84897116776     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.12.025     Document Type: Article

References (26)

1. Usui N. Molecular targeted treatment - new treatment strategy for patients with chronic myeloid leukemia. Rinsho Byori 2004, 52:136-144.
2. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
3. Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008, 100:926-939.
4. Jabbour E., Kantarjian H., Jones D., Talpaz M., Bekele N., O'Brien S., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20:1767-1773.
5. Elias M.H., Baba A.A., Husin A., Abdullah A.D., Hassan R., Sim G.A., et al. Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients. Hematol Rep 2012, 4:e23.
6. Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.
7. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
8. Gorczyca W. Cytogenetics, FISH and molecular testing in hematologic malignancies 2008, 319. Informa Healthcare, United Kingdom.
9. Soverini S., Martinelli G., Amabile M., Poerio A., Bianchini M., Rosti G., et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004, 50:1205-1213.
10. Press R.D., Galderisi C., Yang R., Rempfer C., Willis S.G., Mauro M.J., et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007, 13:6136-6143.
11. Kantarjian H.M., Talpaz M., Giles F., O'Brien S., Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006, 145:913-923.
12. La Rosee P., Deininger M.W. Resistance to imatinib: mutations and beyond. Semin Hematol 2010, 47:335-343.
13. O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.
14. Corbin A.S., Buchdunger E., Pascal F., Druker B.J. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002, 277:32214-32219.
15. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
16. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
17. Ang A.L., Wang Z.P., Yang L.Y., Natesan V., Poon M., Koh L.P., et al. The M351T BCR-ABL kinase mutation is uncommon in asian patients with imatinib-resistant chronic myeloid leukemia: possible relationship with imatinib plasma levels. 50th ASH Annual Meeting and Exposition 2008.
18. Kim S.H., Kim D., Kim D.W., Goh H.G., Jang S.E., Lee J., et al. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol 2009, 27:190-197.
19. Sherbenou D.W., Hantschel O., Kaupe I., Willis S., Bumm T., Turaga L.P., et al. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 2010, 116:3278-3285.
20. Qin Y., Chen S., Jiang B., Jiang Q., Jiang H., Li J., et al. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol 2011, 90:47-52.
21. Branford S., Melo J.V., Hughes T.P. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood 2009, 114:5426-5435.
22. Cang S., Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008, 1:15.
23. Lee T.S., Potts S.J., Kantarjian H., Cortes J., Giles F., Albitar M. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer 2008, 112:1744-1753.
24. Soverini S., Colarossi S., Gnani A., Castagnetti F., Rosti G., Bosi C., et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007, 92:401-404.
25. Jabbour E., Hochhaus A., Cortes J., La Rosee P., Kantarjian H.M. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2010, 24:6-12.
26. Khoury H.J., Cortes J.E., Kantarjian H.M., Gambacorti-Passerini C., Baccarani M., Kim D.W., et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012, 119:3403-3412.